Novel medical approaches for the treatment of Cushing's disease

Journal of Endocrinological Investigation

Volumn 27, Issue 6, 2004, Pages 591-595

  Heaney, A P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cushing's disease; PPAR ligands; Retinoic acid

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINOGLUTETHIMIDE; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; CYPROHEPTADINE; ETOMIDATE; KETANSERIN; KETOCONAZOLE; LIGAND; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RETINOIC ACID; ROSIGLITAZONE; TROGLITAZONE; VALPROIC ACID;

ARTICLE; ATAXIA; CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EDEMA; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEPATITIS; HUMAN; HYPOKALEMIA; HYPOPHYSIS TUMOR; LIVER INJURY; LIVER TOXICITY; NAUSEA; NONHUMAN; PROTEIN EXPRESSION; SEDATION; SIDE EFFECT; TUMOR GROWTH;

EID: 4544232347     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347485     Document Type: Article

References (28)

1. Merrill RM, Feuer EJ, Capocaccia R, Mariotto A. Cancer prevalence estimates based on tumor registry data in the SEER program. Int J Epidemiology 2000, 29: 197-207.
2. Central Brain Tumor Registry of the United States (CBTRUS). http://www.cbtrus.org
3. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG. Trends in incidence of primary brain tumors in the United States, 1985-1994. Neuro-Oncol 2001, 3: 141-51.
4. Freda PU, Wardlaw SL. Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999, 84: 3859-66.
5. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
6. Simmons NE, Alden TD, Thorner MO, Laws ER Jr. Serum cortisol response to transphenoidal surgery for Cushing disease. J Neurosurg 2001, 95: 1-8.
7. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing's disease: A report of 216 cases. Ann Intern Med 1988, 109: 487-93.
8. Hoybye C, Grenback E, Rahn T, Degerblad M, Thoren M, Hulting AL. Adrenocorticotrophic hormone-producing pituitary tumors: 12 to 22-year follow-up after treatment with sterotactic radiosurgery. Neurosurgery 2001, 49: 284-91.
9. Niemann LK. Medical Therapy of Cushing's Disease. Pituitary 2002, 5: 77-82.
10. Morris D, Grossman A. The Medical Management of Cushing's Syndrome. Ann N Y Acad Sci 2002, 970: 119-33.
11. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 1999, 22: 860-5.
12. Verlhest JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991, 35: 169-78.
13. Tabarin A, Navarranne A, Guerin J, Corcuff JB, Parmiex M, Roger P. Use of ketaconazole in the treatment of Cushing's diaease and ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1991, 34: 63-9.
14. Sonino N, Boscaro M, Merola G, Mantero F. Prolonged treatment of Cushing's disease by ketoconazole. J Clin Endocrinol Metab 1985, 61: 718-22.
15. Boscaro M, Sonino N, Rampazzo A, Mantero F. Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing's disease before and after ketoconazole treatment. Clin Endocrinol (Oxf) 1987, 27: 461-7.
16. McCance DR, Ritchie CM, Sheridan H, Atkinson AB. Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1981, 1: 573.
17. Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab 1998, 83: 3542-4.
18. Bertagna X, Bertagna C, Laudat MH, Husson J-M, Girard F, Luton JP. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 1986, 63: 639-43.
19. Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU-486. J Clin Endocrinol Metab 1985, 61:536-50.
20. Kurie JM. The biologic basis for the use of retinoids in cancer prevention and treatment. Curr Opin Oncol 1999, 11:497-502.
21. Pereda-Paez M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2002, 108: 1123-31.
22. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347: 645-60.
23. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 1992, 358: 771-4.
24. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47: 507-14.
25. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996, 45: 1661-9.
26. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391: 79-82.
27. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med 1998, 4: 1046-52.
28. Heaney AP, Fernando M, Yong W, Melmed S. Functional PPAR-γ receptor represents a novel therapeutic target in Cushing's disease. Nat Med 2002, 11: 1281-7.